{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:27:15Z","timestamp":1794274035339,"version":"4.9.0"},"reference-count":39,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>DIS3 gene mutations occur in roughly 10% of patients with multiple myeloma (MM); furthermore, DIS3 expression can be affected by monosomy 13 and del(13q), which occur in approximately 40% of MM cases. Despite several reports on the prevalence of DIS3 mutations, their contribution to the pathobiology of MM remains largely unknown. We took advantage of the large public CoMMpass dataset to investigate the spectrum of DIS3 mutations in MM and its impact on the transcriptome and clinical outcome. We found that the clinical relevance of DIS3 mutations strictly depended on the co-occurrence of del(13q). In particular, bi-allelic DIS3 lesions significantly affected progression-free survival, independently of other predictors of poor clinical outcome, while mono-allelic events mostly affected overall survival. As expected, DIS3 mutations affect the MM transcriptome involving cellular processes and signaling pathways associated with RNA metabolism, and the deregulation of a large number of long non-coding RNA, among which we identified five distinct transcripts as independent predictors of poorer overall survival and nine of worse progression-free survival, with two (AC015982.2 and AL445228.3) predicting both unfavorable outcomes. These findings strongly prompt further studies investigating the relevance of these long non-coding RNA in MM.<\/jats:p>","DOI":"10.3324\/haematol.2021.278342","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T03:58:31Z","timestamp":1620273511000},"page":"921-932","source":"Crossref","is-referenced-by-count":34,"title":["DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome"],"prefix":"10.3324","volume":"107","author":[{"given":"Katia","family":"Todoerti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Ronchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Favasuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Taiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"34805","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-3344.","DOI":"10.1158\/1078-0432.CCR-12-1881"},{"key":"34806","doi-asserted-by":"crossref","unstructured":"Barbieri M, Manzoni M, Fabris S. Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2016; 174(4):642-645.","DOI":"10.1111\/bjh.13793"},{"key":"34807","doi-asserted-by":"crossref","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.","DOI":"10.1038\/ncomms3997"},{"key":"34808","doi-asserted-by":"crossref","unstructured":"Chapman MA, Lawrence MS, Keats JJ. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-472.","DOI":"10.1038\/nature09837"},{"key":"34809","doi-asserted-by":"crossref","unstructured":"Lionetti M, Barbieri M, Manzoni M. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget. 2016; 7(16):21353-21361.","DOI":"10.18632\/oncotarget.7241"},{"key":"34810","doi-asserted-by":"crossref","unstructured":"Lionetti M, Barbieri M, Todoerti K. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget. 2015; 6(28):26129-26141.","DOI":"10.18632\/oncotarget.4674"},{"key":"34811","doi-asserted-by":"crossref","unstructured":"Lohr JG, Stojanov P, Carter SL. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1):91-101.","DOI":"10.1016\/j.ccr.2013.12.015"},{"key":"34812","doi-asserted-by":"crossref","unstructured":"Bolli N, Biancon G, Moarii M. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32(12):2604-2616.","DOI":"10.1038\/s41375-018-0037-9"},{"key":"34813","doi-asserted-by":"crossref","unstructured":"D'Agostino M, Zaccaria GM, Ziccheddu B. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020; 26(18):4832-4841.","DOI":"10.1158\/1078-0432.CCR-20-0951"},{"key":"34814","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019; 33(1):159-170.","DOI":"10.1038\/s41375-018-0196-8"},{"key":"34815","doi-asserted-by":"crossref","unstructured":"Tomecki R, Drazkowska K, Kucinski I. Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target. Nucleic Acids Res. 2014; 42(2):1270-1290.","DOI":"10.1093\/nar\/gkt930"},{"key":"34816","doi-asserted-by":"crossref","unstructured":"Schneider C, Leung E, Brown J, Tollervey D. The N-terminal PIN domain of the exosome subunit Rrp44 harbors endonuclease activity and tethers Rrp44 to the yeast core exosome. Nucleic Acids Res. 2009; 37(4):1127-1140.","DOI":"10.1093\/nar\/gkn1020"},{"key":"34817","doi-asserted-by":"crossref","unstructured":"Lorentzen E, Basquin J, Tomecki R, Dziembowski A, Conti E. Structure of the active subunit of the yeast exosome core, Rrp44: diverse modes of substrate recruitment in the RNase II nuclease family. Mol Cell. 2008; 29(6):717-728.","DOI":"10.1016\/j.molcel.2008.02.018"},{"key":"34818","doi-asserted-by":"crossref","unstructured":"Robinson SR, Oliver AW, Chevassut TJ, Newbury SF. The 3' to 5' exoribonuclease DIS3: from structure and mechanisms to biological functions and role in human disease. Biomolecules. 2015; 5(3):1515-1539.","DOI":"10.3390\/biom5031515"},{"key":"34819","doi-asserted-by":"crossref","unstructured":"Tomecki R, Drazkowska K, Dziembowski A. Mechanisms of RNA degradation by the eukaryotic exosome. Chembiochem. 2010; 11(7):938-945.","DOI":"10.1002\/cbic.201000025"},{"key":"34820","doi-asserted-by":"crossref","unstructured":"Boyle EM, Ashby C, Tytarenko RG. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020; 26(10):2422-2432.","DOI":"10.1158\/1078-0432.CCR-19-1507"},{"key":"34821","doi-asserted-by":"crossref","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017; 14(2):100-113.","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"34822","doi-asserted-by":"crossref","unstructured":"Binder M, Rajkumar SV, Ketterling RP. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017; 7(9):e600.","DOI":"10.1038\/bcj.2017.83"},{"key":"34823","doi-asserted-by":"crossref","unstructured":"Chiecchio L, Dagrada GP, Ibrahim AH. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009; 94(12):1708-1713.","DOI":"10.3324\/haematol.2009.011064"},{"key":"34824","doi-asserted-by":"crossref","unstructured":"Chesi M, Stein CK, Garbitt VM. Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020; 1(1):68-81.","DOI":"10.1158\/0008-5472.BCD-19-0068"},{"key":"34825","doi-asserted-by":"crossref","unstructured":"de Groen FL, Krijgsman O, Tijssen M. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression. Genes Chromosomes Cancer. 2014; 53(4):339-348.","DOI":"10.1002\/gcc.22144"},{"key":"34826","doi-asserted-by":"crossref","unstructured":"Weissbach S, Langer C, Puppe B. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015; 169(1):57-70.","DOI":"10.1111\/bjh.13256"},{"key":"34827","doi-asserted-by":"crossref","unstructured":"Segalla S, Pivetti S, Todoerti K. The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. Nucleic Acids Res. 2015; 43(10):5182-5193.","DOI":"10.1093\/nar\/gkv387"},{"key":"34828","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597.","DOI":"10.1182\/blood-2018-03-840132"},{"key":"34829","doi-asserted-by":"crossref","unstructured":"Schadt EE, Li C, Ellis B, Wong WH. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl. 2001; Suppl 37:120-125.","DOI":"10.1002\/jcb.10073"},{"key":"34830","doi-asserted-by":"crossref","unstructured":"Subramanian A, Tamayo P, Mootha VK. Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.","DOI":"10.1073\/pnas.0506580102"},{"key":"34831","doi-asserted-by":"crossref","unstructured":"Chen L, Li Q, She T. IRE1alpha-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. Leuk Res. 2016; 49:7-12.","DOI":"10.1016\/j.leukres.2016.07.006"},{"key":"34832","doi-asserted-by":"crossref","unstructured":"Sigova AA, Mullen AC, Molinie B. Divergent transcription of long noncoding RNA\/mRNA gene pairs in embryonic stem cells. Proc Natl Acad Sci U S A. 2013; 110(8):2876-2881.","DOI":"10.1073\/pnas.1221904110"},{"key":"34833","doi-asserted-by":"crossref","unstructured":"Tan JY, Smith AAT, Ferreira da Silva M. Cis-acting complex-trait-associated lincRNA expression correlates with modulation of chromosomal architecture. Cell Rep. 2017; 18(9):2280-2288.","DOI":"10.1016\/j.celrep.2017.02.009"},{"key":"34834","doi-asserted-by":"crossref","unstructured":"Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An abundance of bidirectional promoters in the human genome. Genome Res. 2004; 14(1):62-66.","DOI":"10.1101\/gr.1982804"},{"key":"34835","doi-asserted-by":"crossref","unstructured":"Pefanis E, Basu U. RNA exosome regulates AID DNA mutator activity in the B cell genome. Adv Immunol. 2015; 127:257-308.","DOI":"10.1016\/bs.ai.2015.04.002"},{"key":"34836","doi-asserted-by":"crossref","unstructured":"Chlebowski A, Lubas M, Jensen TH, Dziembowski A. RNA decay machines: the exosome. Biochim Biophys Acta. 2013; 1829(6-7):552-560.","DOI":"10.1016\/j.bbagrm.2013.01.006"},{"key":"34837","doi-asserted-by":"crossref","unstructured":"Higgins LG, Hayes JD. Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. Drug Metab Rev. 2011; 43(2):92-137.","DOI":"10.3109\/03602532.2011.567391"},{"key":"34838","doi-asserted-by":"crossref","unstructured":"Xu B, Qin T, Yu J, Giordano TJ, Sartor MA, Koenig RJ. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma. J Biol Chem. 2020; 295(26):8834-8845.","DOI":"10.1074\/jbc.RA120.013530"},{"key":"34839","doi-asserted-by":"crossref","unstructured":"Chapman J, Ng YS, Nicholls TJ. The maintenance of mitochondrial DNA integrity and dynamics by mitochondrial membranes. Life. 2020; 10(9):164.","DOI":"10.3390\/life10090164"},{"key":"34840","doi-asserted-by":"crossref","unstructured":"Davidson L, Francis L, Cordiner RA. Rapid depletion of DIS3, EXOSC10, or XRN2 reveals the immediate impact of exoribonucleolysis on nuclear RNA metabolism and transcriptional control. Cell Rep. 2019; 26(10):2779-2791.e5.","DOI":"10.1016\/j.celrep.2019.02.012"},{"key":"34841","doi-asserted-by":"crossref","unstructured":"Kiss DL, Andrulis ED. Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits. RNA. 2010; 16(4):781-791.","DOI":"10.1261\/rna.1906710"},{"key":"34842","doi-asserted-by":"crossref","unstructured":"Milbury KL, Paul B, Lari A. Exonuclease domain mutants of yeast DIS3 display genome instability. Nucleus. 2019; 10(1):21-32.","DOI":"10.1080\/19491034.2019.1578600"},{"key":"34843","doi-asserted-by":"crossref","unstructured":"Rigby RE, Rehwinkel J. RNA degradation in antiviral immunity and autoimmunity. Trends Immunol. 2015; 36(3):179-188.","DOI":"10.1016\/j.it.2015.02.001"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278342\/73354","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278342\/74294","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10262\/73354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:32Z","timestamp":1794045572000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278342","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}